IN8BIO INC (INAB) Stock Price, Quote, News and Overview
NASDAQ:INAB - Nasdaq - US45674E1091 - Common Stock - Currency: USD
INAB Quote, Performance and Key Statistics
NASDAQ:INAB (7/23/2025, 11:15:52 AM)
2.4208
+0.05 (+2.14%)
The current stock price of INAB is 2.4208 USD. In the past month the price increased by 6.28%. In the past year, price decreased by -90.58%.
INAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.35 | 332.91B | ||
| AMGN | AMGEN INC | 14.78 | 165.01B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 138.95B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 122.18B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 61.82B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.60B | ||
| ARGX | ARGENX SE - ADR | 99.69 | 35.00B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.57 | 32.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.27B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.52B | ||
| INSM | INSMED INC | N/A | 19.37B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B |
Related stock screener links
About INAB
Company Profile
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Company Info
IN8BIO INC
Empire State Building, 350 5Th Avenue, Suite 5330
New York City NEW YORK US
CEO: William Ho
Employees: 39
Phone: 16466006438
IN8BIO INC / INAB FAQ
What is the stock price of IN8BIO INC today?
The current stock price of INAB is 2.4208 USD. The price increased by 2.14% in the last trading session.
What is the ticker symbol for IN8BIO INC stock?
The exchange symbol of IN8BIO INC is INAB and it is listed on the Nasdaq exchange.
On which exchange is INAB stock listed?
INAB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IN8BIO INC stock?
10 analysts have analysed INAB and the average price target is 127.76 USD. This implies a price increase of 5177.39% is expected in the next year compared to the current price of 2.4208. Check the IN8BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IN8BIO INC worth?
IN8BIO INC (INAB) has a market capitalization of 8.33M USD. This makes INAB a Nano Cap stock.
How many employees does IN8BIO INC have?
IN8BIO INC (INAB) currently has 39 employees.
What are the support and resistance levels for IN8BIO INC (INAB) stock?
IN8BIO INC (INAB) has a resistance level at 2.5. Check the full technical report for a detailed analysis of INAB support and resistance levels.
Should I buy IN8BIO INC (INAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INAB, evaluating the profitability, health, valuation and growth aspects
- IN8BIO INC (INAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IN8BIO INC (INAB) Sales and EPS estimates to see what analysts future expectations are.
- IN8BIO INC (INAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IN8BIO INC (INAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- IN8BIO INC (INAB) Stock Chart to make your own analysis
- IN8BIO INC (INAB) Latest news and press-releases to stay up to date.
Does IN8BIO INC (INAB) stock pay dividends?
INAB does not pay a dividend.
When does IN8BIO INC (INAB) report earnings?
IN8BIO INC (INAB) will report earnings on 2025-08-01, after the market close.
What is the Price/Earnings (PE) ratio of IN8BIO INC (INAB)?
IN8BIO INC (INAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.5).
INAB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to INAB. When comparing the yearly performance of all stocks, INAB is a bad performer in the overall market: 99.33% of all stocks are doing better.
INAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INAB. INAB has a bad profitability rating. Also its financial health evaluation is rather negative.
INAB Financial Highlights
Over the last trailing twelve months INAB reported a non-GAAP Earnings per Share(EPS) of -13.5. The EPS increased by 50.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -138.03% | ||
| ROE | -197.63% | ||
| Debt/Equity | 0.01 |
INAB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to INAB. The Buy consensus is the average rating of analysts ratings from 10 analysts.